Patent ID: 8178527

Claim:
A nordihydroguaiaretic acid (NDGA) derivative compound having the following general structure (Formula IV), and its pharmaceutically acceptable salts: wherein X is selected from the group consisting of: -A-R; —(CH 2 ) x Hal, where x is an integer of 1 to 10, and Hal is a halogen atom, and —(CH 2 CH 2 O) y H, where y is an integer of 1 to 10; and a carbamate-bonded group selected from the group consisting of: where n is an integer of 1 to 6, Z 1 is a saturated linear hydrocarbon chain of 2-6 carbons and optionally 1-3 halogen atoms, Z 2 is a 5- to 7-member ring optionally containing 0-3 double bonds and optionally containing 1-3 atoms of any of O, N and S, and Z 3 is methyl or ethyl, wherein when X is -A-R, R is an end group and A is a linear saturated hydrocarbon side chain bonded at one end to the respective hydroxy residue O groups by an ether bond or a carbamate bond and at the other end to a carbon or a heteroatom in the end group R; wherein the side chain A is selected from the group consisting of a C 2 -C 16 linear saturated hydrocarbon chain optionally with 1-5 heteroatoms selected from the group consisting of O, N and S, bonded to the respective hydroxy residue O groups of NGDA through an ether bond; and 1-5 units of a polyethylene glycol (PEG) chain; wherein R is selected from the group consisting of: a 5 to 7 member carbocyclic ring selected from the group consisting of a fully saturated ring with 1 to 3 N, O or S heteroatoms; provided that the ring does not contain just a hetero nitrogen atom and is not pyrrolidine, piperidine or a morphonline group; a ring containing 1 to 3 double bonds with 1 to 3 N, O or S heteroatoms; a ring containing a carbamate bond, a urea bond, a carbonate bond or an amide bond; and a water soluble group selected from the group consisting of an alkali metal salt of sulfonic acid; an alkali metal salt of phosphonic acid; a pharmaceutically acceptable salt; a sugar and a polyhydroxy group.